Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC) -- Ignore unavailable to you. Want to Upgrade?

To: caly who wrote (223)	6/10/2004 1:03:08 PM
From: tuck	Read Replies (1) \| Respond to of 946

>>GENEVA, June 10 /PRNewswire-FirstCall/ -- Arsenic trioxide will be featured in seven presentations at the 9th Congress of the European Hematology Association (EHA). Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; Nuovo Mercato: CTIC) markets TRISENOX® (arsenic trioxide) injection. For a list of presentations at ASH, refer to the table below. To access a complete list of abstracts, refer to the conference website at ehaweb.org . Trisenox(R) (arsenic Trioxide) Presentations Date Time ABSTRACT Title # Fri., June 11 5:00 p.m. 118 The influence of arsenic trioxide on the clonogenic capacity of bone marrow in patients with newly diagnosed chronic phase chronic myelogenous leukemia (CML) Fri., June 11 5:00 p.m. 093 Treatment of new cases of acute promyelocytic leukemia (APL) by arsenic trioxide Fri., June 11 5:00 p.m. 085 Treatment of newly diagnosed patients with APL using intravenous arsenic trioxide Sat., June 12 5:15 p.m. 365 A phase I/II multicenter, safety and efficacy study of combination treatment with melphalan, arsenic and vitamin C (ascorbic acid) (MAC) in patients with relapsed or refractory multiple myeloma Sat., June 12 5:15 p.m. 522 Safety experience with TRISENOX (arsenic trioxide) injection Sat., June 12 5:15 p.m. 467 TRISENOX (arsenic trioxide) in patients with myelodysplastic syndromes (MDS): Preliminary results of a phase I/II study Sun., June 13 9:00 a.m. 801 Glutathione peroxidase activity and glutathione level in patients with relapsed multiple myeloma treated with arsenic trioxide About TRISENOX® TRISENOX® (arsenic trioxide) is marketed by Cell Therapeutics, Inc. (CTI). TRISENOX® was approved for marketing in 2000 by the U.S. Food and Drug Administration to treat patients with relapsed or refractory Acute Promyelocytic Leukemia (APL), a rare, life-threatening form of cancer of the blood. TRISENOX® was granted marketing authorization from the European Commission in March 2002. APL, one of eight subtypes of acute myeloid leukemia (AML), represents 10-15 percent of the more than 20,000 patients diagnosed with AML each year. TRISENOX® is currently being studied in more than 40 clinical trials in a variety of cancers. U.S. marketing approval for TRISENOX® was granted based on results from a U.S. multicenter study in which 40 relapsed APL patients were treated with TRISENOX® 0.15 mg/kg until bone marrow remission or a maximum of 60 days. Thirty-four patients (85 percent) achieved CR. When the results for these 40 patients were combined with those for the 12 patients in a pilot trial, an overall response rate of 87 percent was observed.<< snip Cheers, Tuck